St. Joseph Cancer Center - Clinical Trials: Lung
 
SMALL CELL

Limited:

  • None currently

Extensive:

  • None currently

NON-SMALL CELL

Stage I:

  • SWOG E5597: Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer.
     
  • CTSU C140503: A Phase III Randomized Trial Of Lobectomy Versus Sublobar Resection For Small Peripheral Non-Small Cell Lung Cancer
     
  • SWOG 0720: Phase II ERCC 1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
     

Selected:

  • CTSU E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)
     
  • PSOC 6137:  A Phase II Study of Intermittent Gleevec ® (Imatinib mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older with Advanced Non-small Cell Lung Cancer

Stage III:

  • RTOG 0617: A randomized Phase III Comparison of Standard-Dose (60 GY) Versus High-dose (74 Gy) Conformal radiotherapy with concurrent and consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND#103444) in patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

MESOTHELIOMA

  • None currently

BRONCHIOLOALVEOLAR:

  • SWOG 0635: A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC)

Lung Cancer, Ancillary Study:

  • SWOG9925: Lung Cancer Specimen Repository Protocol, Ancillary

STAGE IIIB AND IV:

  • SWOG 0636: A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas

     

For more information on the above clinical trials: Cheryl Patz, RN, OCN, CCRC, 360.715.4133

Return to previous page

Cancer Services


Cancer Committee


Cancer Program